Prospective association of liver function biomarkers with development of hepatobiliary cancers

Cancer Epidemiology

Volumn 40, Issue , 2016, Pages 179-187

  Stepien, Magdalena ^a   Fedirko, Veronika ^b   Duarte Salles, Talita ^a   Ferrari, Pietro ^a   Freisling, Heinz ^a   Trepo, Elisabeth ^c   Trichopoulou, Antonia ^d,e,f   Bamia, Christina ^d,e   Weiderpass, Elisabete ^g,h,i,j   Olsen, Anja ^k   Tjønneland, Anne ^k   Overvad, Kim ^l   Boutron Ruault, Marie Christine ^m,n,o   Fagherazzi, Guy ^m,n,o   Racine, Antoine ^m,n,o   Kühn, Tilman ^p   Kaaks, Rudolf ^p   Aleksandrova, Krasimira ^q   Boeing, Heiner ^q   Lagiou, Pagona ^e,f,r   Benetou, Vassiliki ^d,e   Trichopoulos, Dimitrios ^d,e,f,r   Palli, Domenico ^s   Grioni, Sara ^t   Tumino, Rosario ^u   Naccarati, Alessio ^v   Panico, Salvatore ^w   Bueno de Mesquita, H Bas ^x,y,z,aa   Peeters, Petra H ^y   Lund, Eiliv ^g   Quirós, J Ramón ^ab   Nápoles, Osmel Companioni ^ac   Sánchez, María José ^ad,ae   Dorronsoro, Miren ^af   Huerta, José María ^ae,ag   Ardanaz, Eva ^ae,ah   Ohlsson, Bodil ^ai   Sjöberg, Klas ^ai,aj   Werner, Mårten ^ak   Nystrom, Hanna ^ak   Khaw, Kay Tee ^al   Key, Timothy J ^am   Gunter, Marc ^z   Cross, Amanda ^z   Riboli, Elio ^z   Romieu, Isabelle ^a   Jenab, Mazda ^a   more..

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b EMORY UNIVERSITY   (United States)

^c Hôpital de Cardiologie Lyon   (France)

^d HELLENIC HEALTH FOUNDATION   (Greece)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^f BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^g UNIVERSITY OF TROMSØ   (Norway)

^h CANCER REGISTRY OF NORWAY   (Norway)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j FOLKHÄLSAN RESEARCH CENTER   (Finland)

^k DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^l AARHUS UNIVERSITY   (Denmark)

^m INSERM   (France)

ⁿ UNIVERSITÉ PARIS SACLAY   (France)

^o INSTITUT GUSTAVE ROUSSY   (France)

^p GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^q GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^r HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^s CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^t NATIONAL CANCER INSTITUTE   (Italy)

^u Cancer Registry and Histopathology Unit   (Italy)

^v Human Genetics Foundation   (Italy)

^w UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^x NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^y UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^z IMPERIAL COLLEGE LONDON   (United Kingdom)

^aa UNIVERSITY OF MALAYA   (Malaysia)

^ab Public Health Dir   (Spain)

^ac CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^ad UNIVERSITY OF GRANADA   (Spain)

^ae CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^af BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^ag DEPARTMENT OF EPIDEMIOLOGY   (Spain)

^ah INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^ai LUND UNIVERSITY   (Sweden)

^aj LUND UNIVERSITY HOSPITAL   (Sweden)

^ak UMEÅ UNIVERSITY   (Sweden)

^al UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^am UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

Biological markers; Hepatobiliary cancer; Liver function test; Nested case control study; Prospective cohort

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; BIOLOGICAL MARKER;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CANCER; BILIARY TRACT CANCER; BILIRUBIN BLOOD LEVEL; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GALLBLADDER CANCER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VATER PAPILLA TUMOR; BILE DUCT NEOPLASMS; BILIARY TRACT NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; COMPARATIVE STUDY; EUROPE; LIVER FUNCTION TEST; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROSPECTIVE STUDY; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BILE DUCT NEOPLASMS; BILIARY TRACT NEOPLASMS; BIOMARKERS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; EUROPE; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84960091550     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2016.01.002     Document Type: Article

References (37)

1. IARC, Estimated incidence mortality and 5-year prevalence. (2012) (accessed 27.08.14). http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
2. Page A.J., Cosgrove D.C., Philosophe B., Pawlik T.M. Hepatocellular carcinoma: diagnosis, management, and prognosis. Surg. Oncol. Clin. N. Am. 2014, 23(2):289-311. 10.1016/j.soc.2013.10.006.
3. Gomaa A.I., Khan S.A., Toledano M.B., Waked I., Taylor-Robinson S.D. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J. Gastroenterol. 2008, 14(27):4300-4308.
4. Michelotti G.A., Machado M.V., Diehl A.M. NAFLD, NASH and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 2013, 10(11):656-665. 10.1038/nrgastro.2013.183.
5. Jinjuvadia R., Patel S., Liangpunsakul S. The association between metabolic syndrome and hepatocellular carcinoma: systemic review and meta-analysis. J. Clin. Gastroenterol. 2014, 48(2):172-177. 10.1097/mcg.0b013e3182a030c4.
6. Augustine M.M., Fong Y. Epidemiology and risk factors of biliary tract and primary liver tumors. Surg. Oncol. Clin. N. Am. 2014, 23(2):171-188. 10.1016/j.soc.2013.10.001.
7. Giannini E.G., Testa R., Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ: Canadian Medical Association Journal = journal de l'Association medicale canadienne 2005, 172(3):367-379. 10.1503/cmaj.1040752.
8. Kim C.H., Park J.Y., Lee K.U., Kim J.H., Kim H.K. Association of serum gamma-glutamyltransferase and alanine aminotransferase activities with risk of type 2 diabetes mellitus independent of fatty liver. Diabetes Metab. Res. Rev. 2009, 25(1):64-69. 10.1002/dmrr.890.
9. Nannipieri M., Gonzales C., Baldi S., Posadas R., Williams K., Haffner S.M., Stern M.P., Ferrannini E. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care 2005, 28(7):1757-1762.
10. Schlesinger S., Aleksandrova K., Pischon T., Jenab M., Fedirko V., Trepo E., Overvad K., Roswall N., Tjonneland A., Boutron-Ruault M.C., Fagherazzi G., Racine A., Kaaks R., Grote V.A., Boeing H., Trichopoulou A., Pantzalis M., Kritikou M., Mattiello A., Sieri S., Sacerdote C., Palli D., Tumino R., Peeters P.H., Bueno-de-Mesquita H.B., Weiderpass E., Quiros J.R., Zamora-Ros R., Sanchez M.J., Arriola L., Ardanaz E., Tormo M.J., Nilsson P., Lindkvist B., Sund M., Rolandsson O., Khaw K.T., Wareham N., Travis R.C., Riboli E., Nothlings U. Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. Ann. Oncol. 2013, 24(9):2449-2455. 10.1093/annonc/mdt204.
11. Lopez J.B., Balasegaram M., Thambyrajah V., Timor J. The value of liver function tests in hepatocellular carcinoma. Malaysian J. Pathol. 1996, 18(2):95-99.
12. Cha J.M., Kim M.H., Lee S.K., Seo D.W., Lee S.S., Lee J.H., Lee S.G., Jang S.J. Clinicopathological review of 61 patients with early bile duct cancer. Clin. Oncol. (R. Coll. Radiol.) 2006, 18(9):669-677.
13. Kunutsor S.K., Apekey T.A., Van Hemelrijck M., Calori G., Perseghin G. Gamma glutamyltransferase, alanine aminotransferase and risk of cancer: systematic review and meta-analysis. Int. J. Cancer 2015, 136(5):1162-1170. 10.1002/ijc.29084.
14. Hann H.W., Wan S., Myers R.E., Hann R.S., Xing J., Chen B., Yang H. Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients. PLoS. One. 2012, 7(10):e47687. 10.1371/journal.pone.0047687.
15. Lin Y.J., Lee M.H., Yang H.I., Jen C.L., You S.L., Wang L.Y., Lu S.N., Liu J., Chen C.J. Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients. PLoS One 2013, 8(4):e61448. 10.1371/journal.pone.0061448.
16. Wen C.P., Lin J., Yang Y.C., Tsai M.K., Tsao C.K., Etzel C., Huang M., Hsu C.Y., Ye Y., Mishra L., Hawk E., Wu X. Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J. Natl. Cancer Inst. 2012, 104(20):1599-1611. 10.1093/jnci/djs372.
17. Van Hemelrijck M., Jassem W., Walldius G., Fentiman I.S., Hammar N., Lambe M., Garmo H., Jungner I., Holmberg L. Gamma-glutamyltransferase and risk of cancer in a cohort of 545,460 persons-the Swedish AMORIS study. Eur. J. Cancer 2011, 47(13):2033-2041. 10.1016/j.ejca.2011.03.010.
18. Riboli E., Hunt K.J., Slimani N., Ferrari P., Norat T., Fahey M., Charrondiere U.R., Hemon B., Casagrande C., Vignat J., Overvad K., Tjonneland A., Clavel-Chapelon F., Thiebaut A., Wahrendorf J., Boeing H., Trichopoulos D., Trichopoulou A., Vineis P., Palli D., Bueno-De-Mesquita H.B., Peeters P.H., Lund E., Engeset D., Gonzalez C.A., Barricarte A., Berglund G., Hallmans G., Day N.E., Key T.J., Kaaks R., Saracci R. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002, 5(6B):1113-1124. 10.1079/phn2002394.
19. Riboli E., Kaaks R. The EPIC project: rationale and study design. European Prospective Investigation into Cancer and Nutrition. Int. J. Epidemiol. 1997, 26(Suppl. 1):S6-14.
20. Trichopoulos D., Bamia C., Lagiou P., Fedirko V., Trepo E., Jenab M., Pischon T., Nöthlings U. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. J. Natl. Cancer Inst. 2011, 103:1-10.
21. Lee J.H., Kim D., Kim H.J., Lee C.H., Yang J.I., Kim W., Kim Y.J., Yoon J.H., Cho S.H., Sung M.W., Lee H.S. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Digestive Liver Dis. 2010, 42(7):503-508. 10.1016/j.dld.2009.08.002.
22. Choi J.W. Association between elevated serum hepatic enzyme activity and total body fat in obese humans. Ann. Clin. Lab. Sci. 2003, 33(3):257-264.
23. Jang E.S., Jeong S.H., Hwang S.H., Kim H.Y., Ahn S.Y., Lee J., Lee S.H., Park Y.S., Hwang J.H., Kim J.W., Kim N., Lee D.H. Effects of coffee, smoking, and alcohol on liver function tests: a comprehensive cross-sectional study. BMC Gastroenterol. 2012, 12:145. 10.1186/1471-230x-12-145.
24. Whitfield J.B. Gamma glutamyl transferase. Crit. Rev. Clin. Lab. Sci. 2001, 38(4):263-355. 10.1080/20014091084227.
25. Zhao J., Zhao Y., Wang H., Gu X., Ji J., Gao C. Association between metabolic abnormalities and HBV related hepatocelluar carcinoma in Chinese: a cross-sectional study. Nutr. J. 2011, 10:49. 10.1186/1475-2891-10-49.
26. Jiang S., Jiang D., Tao Y. Role of gamma-glutamyltransferase in cardiovascular diseases. Exp. Clin. Cardiol. 2013, 18(1):53-56.
27. Savini I., Catani M.V., Evangelista D., Gasperi V., Avigliano L. Obesity-associated oxidative stress: strategies finalized to improve redox state. Int. J. Mol. Sci. 2013, 14(5):10497-10538. 10.3390/ijms140510497.
28. Hall P., Cash J. What is the real function of the liver 'function' tests?. Ulster Med. J. 2012, 81(1):30-36.
29. Aragon G., Younossi Z.M. When and how to evaluate mildly elevated liver enzymes in apparently healthy patients. Cleve. Clin. J. Med. 2010, 77(3):195-204. 10.3949/ccjm.77a.09064.
30. Zucker S.D., Horn P.S., Sherman K.E. Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer. Hepatology 2004, 40(4):827-835. 10.1002/hep.20407.
31. Wen C.P., Zhang F., Liang D., Wen C., Gu J., Skinner H., Chow W.H., Ye Y., Pu X., Hildebrandt M.A., Huang M., Chen C.H., Hsiung C.A., Tsai M.K., Tsao C.K., Lippman S.M., Wu X. The ability of bilirubin in identifying smokers with higher risk of lung cancer: a large cohort study in conjunction with global metabolomic profiling. Clin. Cancer Res. 2015, 21(1):193-200. 10.1158/1078-0432.ccr-14-0748.
32. Ching S., Ingram D., Hahnel R., Beilby J., Rossi E. Serum levels of micronutrients, antioxidants and total antioxidant status predict risk of breast cancer in a case control study. J. Nutr. 2002, 132(2):303-306.
33. Erlinger S., Arias I.M., Dhumeaux D. Inherited disorders of bilirubin transport and conjugation: new insights into molecular mechanisms and consequences. Gastroenterology 2014, 146(7):1625-1638. 10.1053/j.gastro.2014.03.047.
34. Carr B.I., Guerra V., Giannini E.G., Farinati F., Ciccarese F., Ludovico Rapaccini G., Di Marco M., Benvegnu L., Zoli M., Borzio F., Caturelli E., Chiaramonte M., Trevisani F. Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype. Semin. Oncol. 2014, 41(2):252-258. 10.1053/j.seminoncol.2014.03.006.
35. Kundur A.R., Singh I., Bulmer A.C. Bilirubin, platelet activation and heart disease: a missing link to cardiovascular protection in Gilbert's syndrome?. Atherosclerosis 2015, 239(1):73-84. 10.1016/j.atherosclerosis.2014.12.042.
36. Mendes F.D., Lindor K.D. Primary sclerosing cholangitis. Clin. Liver Dis. 2004, 8(1):195-211. 10.1016/s1089-3261(03) 00127-2.
37. Botros M., Sikaris K.A. The De Ritis ratio: the test of time. Clin. Biochem. Rev./Aust. Assoc. Clin. Biochem. 2013, 34(3):117-130.